Clinical Trials Logo

Osteoporosis clinical trials

View clinical trials related to Osteoporosis.

Filter by:

NCT ID: NCT00676312 Completed - Clinical trials for Postmenopausal Osteoporosis

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects

Start date: May 2008
Phase: Phase 1
Study type: Interventional

This study is designed to investigate the safety and tolerability of PTH134 in healthy subjects and to assess the exposure from PTH134.

NCT ID: NCT00675688 Completed - Osteoporosis Clinical Trials

Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women

Start date: April 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.

NCT ID: NCT00674453 Completed - Bone Loss Clinical Trials

The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation

LACE
Start date: September 2004
Phase: Phase 2
Study type: Interventional

The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.

NCT ID: NCT00671944 Completed - Osteoporosis Clinical Trials

Long-term Nutritional Intervention Study to Determine How Protein Affects Calcium Metabolism

Start date: May 2003
Phase: Phase 1
Study type: Interventional

Osteoporosis is a major health problem in men and women in this country and the incidence of this disease is rising. We think that environmental factors such as nutrition may play a role in the increasing prevalence of osteoporosis. In particular, we think that a diet that is too low in protein may be contributing to bone loss. The primary purpose of this study is to compare the long-term impact of a low protein diet on measures of bone and calcium metabolism.

NCT ID: NCT00670501 Completed - Clinical trials for Osteoporosis, Postmenopausal

Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis

Start date: August 1996
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to demonstrate a reduction in the proportion of new vertebral fractures in postmenopausal women with osteoporosis following 3-years of treatment with 20 and 40 mcg/day of teriparatide plus calcium and vitamin D compared with calcium and vitamin D alone.

NCT ID: NCT00670319 Completed - Clinical trials for Osteoporosis, Postmenopausal

Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis

MORE
Start date: November 1994
Phase: Phase 3
Study type: Interventional

To study the effect of long-term treatment with raloxifene, compared with placebo, on the rate of new vertebral fractures in osteoporotic postmenopausal women with and without existing vertebral fractures.

NCT ID: NCT00668447 Completed - Osteoporosis Clinical Trials

Soy and Isoflavones Effect on Bone

Start date: November 2001
Phase: Phase 4
Study type: Interventional

The purpose of this study is to test the effect of 1 year of added dietary soy protein and/or soy isoflavones on bone mineral density in late postmenopausal women.

NCT ID: NCT00668330 Completed - Clinical trials for Systemic Lupus Erythematosus

Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus

Start date: April 2007
Phase: Phase 4
Study type: Interventional

The primary aim of the present study was to investigate the prevalence of low bone mineral density (BMD) and vertebral fractures, as determined by a standardized assessment, and to elucidate the role of bone qualities, including micro-architecture, bone remodeling, bone turnover, mineralization and inflammation on bone density and prevalent vertebral fractures in a large population of systemic lupus erythematosus (SLE) patients. The secondary aim of the study is to evaluate the following parameters in women with steroid induced OP (SIOP) before and after 1 year of treatment using: 1. The changes in BMD using dual energy X-ray absorptiometry (DXA) 2. Bone mineralization and architecture in-vivo using a newly available high-resolution human micro-computed tomography (ExtremCT), which can provide us with new insights into how the degree and distribution of mineralization are affected by long-term oral Ibandronate treatment. 3. Changes in perfusion and marrow edema before and after treatment of Ibandronate using dynamic Magnetic Resonance Imaging (MRI) in these patients with SIOP. 4. The investigators prospectively evaluate the correlation between the changes in brachial arterial endothelial function and lumbar spine BMD in female lupus patients over the period of 1 year.

NCT ID: NCT00666640 Completed - Osteoporosis Clinical Trials

3D Imaging of the Hip Using DXA

3DScans
Start date: May 2008
Phase: N/A
Study type: Observational

The study aims to determine the efficacy and best methods for predicting hip fractures and diagnosing post-menopausal osteoporosis using three dimensional structural engineering models (SEMs) of proximal femoral bone produced using a Hologic Discovery duel-energy x-ray absorptiometry scanner and Hologic's new 3D Hip(TM) software in comparison to three dimensional SEMs produced using quantitative computed tomography - the current gold standard.

NCT ID: NCT00666627 Completed - Clinical trials for Post-menopausal Osteoporosis

Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects

Start date: April 2007
Phase: Phase 2
Study type: Interventional

A study to determine if the three licensed bisphosphonates (alendronate, ibandronate and risedronate):a) affect the peripheral skeleton differently, as assessed by quantitative ultrasound of bone (QUS), peripheral quantitative computed tomography (pQCT) and dual−energy x−ray absorptiometry (DXA)? b) have different effects on bone cells and their activity as assessed by flow cytometry and biochemical markers of bone cell activity? The aim of the study is to compare the effects of three licensed bisphosphonates on bone quantity and quality. There has been no such study before. Most of the measures of bone quantity and quality used in this protocol have not been studied with any of these three agents. The novelty of the study necessitates the establishment of reference ranges and this explains the need for the inclusion of a group of young women.